TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02544503

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Single-pulse Transcranial Magnetic Stimulation (TMS)
Description: Single-pulse Transcranial Magnetic Stimulation (TMS) is a brief magnetic pulse that is applied through a coil to the section of the head that overlays the motor cortex of the brain. Subjects will be comfortably seated in a dental chair surrounded by a frame that carries a coil holder to assist with the application of TMS to the brain. Single-pulse transcranial magnetic stimulation (TMS) will be administered at study visits.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Single-pulse Transcranial Magnetic Stimulation (TMS)
Description: Single-pulse Transcranial Magnetic Stimulation (TMS) is a brief magnetic pulse that is applied through a coil to the section of the head that overlays the motor cortex of the brain. Subjects will be comfortably seated in a dental chair surrounded by a frame that carries a coil holder to assist with the application of TMS to the brain. Single-pulse transcranial magnetic stimulation (TMS) will be administered at study visits.
Study: NCT00354172

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total body irradiation (TBI)
Description: TBI 165 Gray (cGy) will be given twice daily for a total dose of 1320 cGy (days~-16 to -13).
Study: NCT02544503

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Paired-pulse Transcranial Magnetic Stimulation (ppTMS)
Description: Paired-pulse Transcranial Magnetic Stimulation (ppTMS) is two brief sequential magnetic pulses that are applied through a coil to the section of the head that overlays the motor cortex of the brain. Subjects will be comfortably seated in a dental chair surrounded by a frame that carries a coil holder to assist with the application of TMS to the brain. Paired-pulse transcranial magnetic stimulation (ppTMS) will be administered at study visits.
Study: NCT03287908

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 701
Description: Subjects will receive IV infusions of AMG 701.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 701
Description: Subjects will receive IV infusions of AMG 701.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 701
Description: Subjects will receive IV infusions of AMG 701.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pomalidomide
Description: Subjects will receive oral capsules of pomalidomide.
Study: NCT02544503

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Paired-pulse Transcranial Magnetic Stimulation (ppTMS)
Description: Paired-pulse Transcranial Magnetic Stimulation (ppTMS) is two brief sequential magnetic pulses that are applied through a coil to the section of the head that overlays the motor cortex of the brain. Subjects will be comfortably seated in a dental chair surrounded by a frame that carries a coil holder to assist with the application of TMS to the brain. Paired-pulse transcranial magnetic stimulation (ppTMS) will be administered at study visits.
Study: NCT01507285

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liraglutide
Description: Initial single dose followed by subsequent multiple s.c. (under the skin) doses on several dose levels (1.25, 5, 7.5, 10 and 12.5 mcg/kg). Each subject will be allocated to one dose level only

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Initial single dose followed by subsequent multiple s.c. (under the skin) doses
Study: NCT03287908

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pomalidomide
Description: Subjects will receive oral capsules of pomalidomide.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Subjects will receive IV injections or oral dexamethasone.
Study: NCT02216214

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirabegron
Description: oral tablet
Study: NCT02544503

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Low-frequency Repetitive Transcranial Magnetic Stimulation (rTMS)
Description: Low-frequency Repetitive Transcranial Magnetic Stimulation (rTMS) is a sequence of brief magnetic pulses that are applied at 0.1 Hz frequency at low intensity through an air-cooled coil to the section of the head that overlays the motor cortex of the brain. Subjects will be comfortably seated in a dental chair surrounded by a frame that carries a coil holder to assist with the application of TMS to the brain. Low-frequency repetitive transcranial magnetic stimulation (rTMS) will be administered at study visits.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Low-frequency Repetitive Transcranial Magnetic Stimulation (rTMS)
Description: Low-frequency Repetitive Transcranial Magnetic Stimulation (rTMS) is a sequence of brief magnetic pulses that are applied at 0.1 Hz frequency at low intensity through an air-cooled coil to the section of the head that overlays the motor cortex of the brain. Subjects will be comfortably seated in a dental chair surrounded by a frame that carries a coil holder to assist with the application of TMS to the brain. Low-frequency repetitive transcranial magnetic stimulation (rTMS) will be administered at study visits.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sham Motor Cortex Stimulation
Description: Sham motor cortex stimulation will be applied at study visits.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sham Motor Cortex Stimulation
Description: Sham motor cortex stimulation will be applied at study visits.
Study: NCT02216214

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral tablet
Study: NCT02832544

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban (20 mg)
Description: Rivaroxaban is non-inferior to VKAs for the prevention of stroke or systemic embolism in patients with AF/flutter and RVHD and potentially superior to VKAs.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin K antagonists (VKA)
Study: NCT00308204

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Raptiva
Description: injection
Study: NCT02089022

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physiotherapy resources
Description: The application of ice has been accomplished by means of a plastic bag containing 1.5 kg of crushed ice. The duration of the application was 30 minutes. The use of shortwave diathermy was performed by means of rectangular electrodes having a duration of 20 minutes.
Study: NCT05993299

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letetresgene autoleucel
Description: Letetresgene autoleucel will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide will be used as a lymphodepleting chemotherapy.
Study: NCT04157803

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Acetic acid % spray
Description: If during a videcolonoscopy a polyp is found with suspicion of tubular, tubulovillious or Serrated adenoma, the endoscopist will proceed to stain it using diffuser and acetic acid at a concentration of 3%. The presence or not of the aceto-whitening reaction will be evaluated, understanding it as the persistence of white staining of the polyp at one minute or three minutes, standing out from the surrounding mucosa.~In case of positive staining it will be considered homogeneous if the staining is uniform on the surface of the polyp or heterogeneous if it is done irregularly.
Study: NCT05993299

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Fludarabine will be used as a lymphodepleting chemotherapy.
Study: NCT04501406

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pioglitazone
Description: An insulin-sensitizer FDA-approved to treat hyperglycemia caused by type 2 diabetes.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo looks just like pioglitazone and is given in the same way but has no active drug in it.
Study: NCT03168828

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trospium-Releasing Intravesical System (TAR-302-5018)
Description: TAR-302-5018 is a passive, nonresorbable trospium-releasing intravesical system whose primary mode of action is the controlled release of trospium into the bladder over a 42-day period.
Study: NCT03264365

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention
Description: Intervention (plus standard care)~* Patients photographs during the ICU-stay,~* Written information about life after ICU~* First consultation face-to-face in hospital setting at three months after ICU~* Visit ICU and photographs given~* Consultations as needed
Study: NCT00996463

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Electro-thermo-coagulation
Description: Electro-thermo-coagulation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium Stibogluconate
Description: Intralesional injection of sodium stibogluconate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DAC N-055
Description: Moist wound treatment with DAC N-055 (German officinal drug of the German drug codex)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DAC N-055
Description: Moist wound treatment with DAC N-055 (German officinal drug of the German drug codex)
Study: NCT03789916

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Description: 90 mg bis in die

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: acetylsalicylic acid
Description: 100 mg die

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: acetylsalicylic acid
Description: 100 mg die
Study: NCT02857608

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lymphoseek
Study: NCT00483470

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Hepatitis A vaccine AVAXIM 80U
Description: 0.5 mL, Intramuscular

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Hepatitis A vaccine (HAVRIX 720)
Description: 0.5 mL, Intramuscular
Study: NCT03306940

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum Toxin Type A
Description: patients were injected to the normal side with dose of 1.25 units/per site

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Botulinum Toxin Type A
Description: patients were injected to the normal side with dose of 1.25 units/per site
Study: NCT00226057

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Raptiva
Description: Open Label
Study: NCT03083366

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PrimeAdvanced Surescan 97702 Neurostimulator - Medtronic (Minneapolis, MN)
Description: Bilateral s S3 sacral neuromodulation delivered via the PrimeAdvanced Surescan 97702 Neurostimulator - Medtronic (Minneapolis, MN)
Study: NCT02621307

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Salba

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Flax

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Control
Study: NCT01371981

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Asparaginase
Description: Given IM

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Asparaginase
Description: Given IM
Study: NCT03009851

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: OBCHI
Description: Occupation-based cultural heritage intervention emphasizing the cultural background of residents in LTC settings.
Study: NCT01966822

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dolutegravir, 50mg every 24 hours
Description: Dolutegravir, 50mg every 24 hours

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Protease Inhibitor/ritonavir
Description: Protease Inhibitor/ritonavir
Study: NCT01371981

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Asparaginase
Description: Given IM
Study: NCT00964392

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Atrial fibrillation ablation
Description: Radiofrequency ablation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Atrial fibrillation ablation
Description: Radiofrequency ablation
Study: NCT03211169

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsies of bile duct stricture with pediatric biopsy forceps
Description: Biopsies of the stricture will be taken to evaluate diagnostic yield of Pediatric Biopsy Forceps

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biopsies of bile duct stricture with cholangioscopy-directed biopsies
Description: Biopsies of the stricture will be taken to evaluate diagnostic yield of cholangioscopy-directed biopsies
Study: NCT01371981

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Asparaginase
Description: Given IM

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Asparaginase
Description: Given IM

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Given IT or IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Given IT or IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Given IT or IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Given IT or IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Given IT or IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Given IT or IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daunorubicin Hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daunorubicin Hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daunorubicin Hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daunorubicin Hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daunorubicin Hydrochloride
Description: Given IV
Study: NCT02802410

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IQ-Tape
Description: RMS-values of leg muscles at pre-activation (50ms) before ground-contact and post-activation 0-30ms and 30 - 150ms after ground-contact during drop-jump, running and stair climbing.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Kinesiotape
Description: RMS-values of leg muscles at pre-activation (50ms) before ground-contact and post-activation 0-30ms and 30 - 150ms after ground-contact during drop-jump, running and stair climbing.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No-Tape
Description: RMS-values of leg muscles at pre-activation (50ms) before ground-contact and post-activation 0-30ms and 30 - 150ms after ground-contact during drop-jump, running and stair climbing.
Study: NCT01037218

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Udenafil
Description: Tablets via oral administration before an attempt at sexual intercourse.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Udenafil
Description: Tablets via oral administration before an attempt at sexual intercourse.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Udenafil
Description: Tablets via oral administration before an attempt at sexual intercourse.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablets via oral administration before an attempt at sexual intercourse.
Study: NCT01371981

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daunorubicin Hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitoxantrone Hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitoxantrone Hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitoxantrone Hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitoxantrone Hydrochloride
Description: Given IV
Study: NCT01773707

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline given as 30 minute IV infusion
Study: NCT01371981

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitoxantrone Hydrochloride
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study: NCT01037218

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Tablets via oral administration before an attempt at sexual intercourse.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Tablets via oral administration before an attempt at sexual intercourse.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Tablets via oral administration before an attempt at sexual intercourse.
Study: NCT04454255

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: FunSpeech
Description: Weekly sessions of regular speech therapy as regularly performed for the individual participant (one hour, once or twice a week) and parent-supervised home use of a serious game. It will be recommended to use FunSpeech every day, 15 minutes per day.
Study: NCT01371981

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT04152122

Intervention type: DIAGNOSTIC_TEST
Intervention: The dynamic stereopsis test
Description: The characteristics of preoperative dynamic stereopsis in 83 intermittent exotropia patients and its associations with clinical features were analysed, and the prognosis was followed up on the 1st day and 2nd, 6th and 12nd months postoperatively.
Study: NCT01371981

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT04454255

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Control
Description: Weekly sessions of regular speech therapy as regularly performed for the individual participant (one hour, once or twice a week).
Study: NCT04160650

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Educational nursing intervention on nutrition intake related chemotherapy induced side-effects' self-care among the patients with colorectal cancer
Description: This is an educational intervention which aims to answer the questions:~1. In patients with CRC what is the effect of empowering education versus standard education on knowledge level in 4 months follow-up?~2. In patients with CRC what is the effect of empowering education versus standard education on activation level related to nutrition impact side effects' self-care in 4 months follow-up?~3. In patients with CRC what is the effect of empowering education versus standard education on malnutrition risk in 4 months follow-up?~4. In patients with CRC what is the effect of empowering education versus standard education on QoL in 4 months follow-up?